Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
93 studies found for:    "idiopathic inflammatory myopathy"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:
2 Recruiting Environmental Risk Factors for Myositis in Military Personnel
Conditions: Dermatomyositis;   Adult Polymyositis;   Inclusion Body Myositis;   Myositis
Intervention:
3 Recruiting Adult and Juvenile Myositis
Conditions: Dermatomyositis;   Polymyositis;   Inclusion Body Myositis
Intervention:
4 Completed Anakinra in Myositis
Conditions: Polymyositis;   Dermatomyositis;   Inclusion Body Myositis
Intervention: Drug: Anakinra
5 Completed Immune Abnormalities in Sporadic Inclusion Body Myositis
Conditions: Sporadic;   Inclusion Body;   Myositis
Intervention:
6 Completed Alemtuzumab to Treat Sporadic Inclusion Body Myositis
Condition: Myositis, Inclusion Body
Intervention: Drug: Alemtuzumab (Campath)
7 Completed Arimoclomol in Sporadic Inclusion Body Myositis
Condition: Inclusion Body Myositis
Interventions: Drug: Arimoclomol;   Other: Placebo
8 Recruiting Belimumab in Myositis
Condition: Myositis
Intervention: Drug: Belimumab + standard of care (randomized phase)
9 Completed Lithium in Inclusion Body Myositis (IBM)
Condition: Inclusion Body Myositis
Intervention:
10 Enrolling by invitation Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
Conditions: Becker Muscular Dystrophy;   Sporadic Inclusion Body Myositis
Intervention: Biological: rAAV1.CMV.huFollistatin344
11 Recruiting Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis (sIBM)
Intervention: Drug: BYM338 (Bimagrumab)
12 Completed Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Biological: BYM338;   Biological: Placebo
13 Completed Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention:
14 Completed Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis
Condition: Inclusion Body Myositis
Intervention: Drug: Etanercept
15 Enrolling by invitation Blood-flow Restricted Exercise in Inclusion Body Myositis
Condition: Sporadic Inclusion Body Myositis
Interventions: Other: Blood-flow restricted training;   Drug: Care as usual
16 Recruiting Exercise in Sjogren and Myositis
Conditions: Primary Sjogren´s Syndrome;   Myositis
Intervention: Other: Exercise training
17 Recruiting Study and Treatment of Inflammatory Muscle Diseases
Conditions: Autoimmune Disease;   Dermatomyositis;   Inclusion Body Myositis;   Myositis;   Polymyositis
Intervention:
18 Completed Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Conditions: Autoimmune/Connective Tissue Diseases;   Idiopathic Inflammatory Myopathies;   IIM
Intervention:
19 Recruiting Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Conditions: Myositis;   Polymyositis;   Dermatomyositis;   Myositis, Inclusion Body
Intervention: Procedure: MRI-oriented muscle biopsy
20 Active, not recruiting Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Condition: Sporadic Inclusion Body Myositis
Interventions: Drug: BYM338/bimagrumab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years